Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 16 de 16
Filter
1.
Dysphagia ; 32(2): 250-260, 2017 04.
Article in English | MEDLINE | ID: mdl-27873090

ABSTRACT

Early and reliable screening for oropharyngeal dysphagia (OD) symptoms in at-risk populations is important and a crucial first stage in effective OD management. The Eating Assessment Tool (EAT-10) is a commonly utilized screening and outcome measure. To date, studies using classic test theory methodologies report good psychometric properties, but the EAT-10 has not been evaluated using item response theory (e.g., Rasch analysis). The aim of this multisite study was to evaluate the internal consistency and structural validity and conduct a preliminary investigation of the cross-cultural validity of the EAT-10; floor and ceiling effects were also checked. Participants involved 636 patients deemed at risk of OD, from outpatient clinics in Spain, Turkey, Sweden, and Italy. The EAT-10 and videofluoroscopic and/or fiberoptic endoscopic evaluation of swallowing were used to confirm OD diagnosis. Patients with esophageal dysphagia were excluded to ensure a homogenous sample. Rasch analysis was used to investigate person and item fit statistics, response scale, dimensionality of the scale, differential item functioning (DIF), and floor and ceiling effect. The results indicate that the EAT-10 has significant weaknesses in structural validity and internal consistency. There are both item redundancy and lack of easy and difficult items. The thresholds of the rating scale categories were disordered and gender, confirmed OD, and language, and comorbid diagnosis showed DIF on a number of items. DIF analysis of language showed preliminary evidence of problems with cross-cultural validation, and the measure showed a clear floor effect. The authors recommend redevelopment of the EAT-10 using Rasch analysis.


Subject(s)
Deglutition Disorders/diagnosis , Health Status , Health Surveys , Aged , Aged, 80 and over , Culture , Europe , Female , Humans , Male , Middle Aged , Psychometrics , Reproducibility of Results , Self Report
2.
Biomed Res Int ; 2016: 6086894, 2016.
Article in English | MEDLINE | ID: mdl-27722170

ABSTRACT

Introduction. Patients with head and neck cancer suffer from various impairments due to the primary illness, as well as secondary consequences of the oncological treatment. This systematic review describes the effects of radiotherapy and/or chemotherapy on the functions of the upper aerodigestive tract in patients with head and neck cancer. Methods. A systematic literature search was performed by two independent reviewers using the electronic databases PubMed and Embase. All dates up to May 2016 were included. Results. Of the 947 abstracts, sixty articles met the inclusion criteria and described one or more aspects of the sequelae of radiotherapy and/or chemotherapy. Forty studies described swallowing-related problems, 24 described voice-related problems, seven described trismus, and 25 studies described general quality of life. Only 14 articles reported that speech pathologists conducted the interventions, of which only six articles described in detail what the interventions involved. Conclusion. In general, voice quality improved following intervention, whereas quality of life, dysphagia, and oral intake deteriorated during and after treatment. However, as a consequence of the diversity in treatment protocols and patient characteristics, the conclusions of most studies cannot be easily generalised. Further research on the effects of oncological interventions on the upper aerodigestive tract is needed.


Subject(s)
Chemoradiotherapy/statistics & numerical data , Deglutition Disorders/epidemiology , Head and Neck Neoplasms/epidemiology , Head and Neck Neoplasms/therapy , Speech Disorders/epidemiology , Trismus/epidemiology , Aged , Causality , Comorbidity , Humans , Incidence , Middle Aged , Risk Factors , Voice Disorders/epidemiology
4.
Semin Oncol ; 17(1 Suppl 2): 20-4, 1990 Feb.
Article in English | MEDLINE | ID: mdl-2154855

ABSTRACT

A randomized study with cisplatin (120 mg/m2) or carboplatin (325 mg/m2) plus etoposide (100 mg/m2, days 1 to 3) in 162 evaluable patients with advanced non-small cell lung cancer (NSCLC) compared response and survival after treatment. No statistically significant difference in survival rates was detected; median survival was 25 weeks for patients receiving cisplatin and 24 weeks for those receiving carboplatin. The objective response rate was 25% for cisplatin plus etoposide and 20% for carboplatin plus etoposide. Granulocytopenia, diarrhea, and nephrotoxicity were significantly more frequent with cisplatin plus etoposide than with carboplatin plus etoposide. Severe nausea and/or vomiting occurred during 59 of 77 courses (77%) with cisplatin and 48 of 75 (64%) with carboplatin (P = .13). Unlike cisplatin plus etoposide, carboplatin plus etoposide was administered on an outpatient basis. At the dose used in the present study, carboplatin plus etoposide was as effective as but less toxic than cisplatin plus etoposide for NSCLC and could be given more easily.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Carcinoma, Non-Small-Cell Lung/drug therapy , Lung Neoplasms/drug therapy , Adenocarcinoma/drug therapy , Adenocarcinoma/mortality , Adult , Aged , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Carboplatin , Carcinoma, Non-Small-Cell Lung/mortality , Carcinoma, Squamous Cell/drug therapy , Carcinoma, Squamous Cell/mortality , Cisplatin/administration & dosage , Etoposide/administration & dosage , Female , Humans , Lung Neoplasms/mortality , Male , Middle Aged , Organoplatinum Compounds/administration & dosage , Randomized Controlled Trials as Topic , Survival Rate
5.
J Clin Oncol ; 7(8): 1087-92, 1989 Aug.
Article in English | MEDLINE | ID: mdl-2547028

ABSTRACT

We conducted a randomized study comparing the survival after treatment with cisplatin (120 mg/m2) or cisplatin plus etoposide (100 mg/m2 on days 1, 2, and 3) in 162 evaluable patients with advanced non-small-cell lung cancer (NSCLC). No statistically significant difference in survival was detected; the median survival was 26 and 22 weeks, respectively, for patients receiving cisplatin and for those receiving cisplatin plus etoposide. The objective response rate was 19% for cisplatin and 26% for the combination; the corresponding response rates were 17% and 43% in patients with limited disease. No significant differences were detected between the two study arms as far as toxicity was concerned, except for alopecia and granulocytopenia, which occurred more frequently in patients treated with cisplatin plus etoposide.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Carcinoma, Non-Small-Cell Lung/drug therapy , Cisplatin/therapeutic use , Etoposide/therapeutic use , Lung Neoplasms/drug therapy , Adenocarcinoma/drug therapy , Adult , Aged , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Carcinoma, Squamous Cell/drug therapy , Cisplatin/administration & dosage , Cisplatin/adverse effects , Etoposide/administration & dosage , Etoposide/adverse effects , Female , Humans , Male , Middle Aged , Prognosis , Random Allocation
6.
Rev Stomatol Chir Maxillofac ; 89(2): 112-6, 1988.
Article in French | MEDLINE | ID: mdl-3165544

ABSTRACT

Seventy-four temporomandibular arthrographic examinations, mostly involving paracentesis of the menisco-condylar compartment, provided the means for visualizing normal and pathologic aspects of both reducible and non-reducible meniscal dislocations, and of perforations. Findings included distension of the bilaminar zone and adhesions. Post modeling condyloplasty status was noted. At present, arthrography seems to be the most reliable test, as well as being the easiest to perform and the least expensive one for visualizing menisco-condylar abnormalities.


Subject(s)
Arthrography , Temporomandibular Joint/diagnostic imaging , Adolescent , Adult , Arthrography/methods , Cartilage, Articular/diagnostic imaging , Contrast Media , Female , Humans , Male , Mandibular Condyle/diagnostic imaging , Middle Aged , Temporomandibular Joint Disorders/diagnostic imaging
8.
Thorax ; 35(8): 603-10, 1980 Aug.
Article in English | MEDLINE | ID: mdl-7444828

ABSTRACT

We investigated pulmonary mechanics in 25 patients, 9 to 55 years of age, with a variety of generalised neuromuscular diseases and variable degrees of respiratory muscle weakness. The average degree of inspiratory muscle force was 39.2% (range 8-83%) of predicted. The lung volume restriction far exceeded that expected for the degree of muscle weakness: the observed decrement in respiratory muscle force should, theoretically, decrease vital capacity to 78% of its control value, while the mean VC in our patients was only 50% of predicted. Analysis of lung pressure-volume curves indicated that the two principal causes of the disproportionate loss of lung volume were a reduction in lung distensibility probably caused by widespread microatelectasis, and a decrease in the outward pull of the chest wall. Because it reflects both direct (loss of distending pressure) and secondary (alterations in the elastic properties of the lungs and chest wall) effects of respiratory muscle weakness on lung function, we conclude that, in these patients, the vital capacity remains the most useful measurement to follow evolution of the disease process or response to treatment.


Subject(s)
Lung/physiopathology , Neuromuscular Diseases/physiopathology , Adolescent , Adult , Child , Female , Humans , Lung Compliance , Lung Volume Measurements , Male , Middle Aged , Muscles/physiopathology , Respiration , Vital Capacity
9.
Laryngoscope ; 90(1): 145-51, 1980 Jan.
Article in English | MEDLINE | ID: mdl-6986007

ABSTRACT

Ninety-one hay fever patients received either 0.5 mg/kg oxatomide b.i.d. or 0.4 mg/kg diphenhydramine b.i.d. in a two-month double-blind study. If necessary this dose could be doubled. The results showed that fewer oxatomide patients needed to double this starting dose and to use a nasal spray. Oxatomide proved to be more effective than diphenhydramine in limiting the severity of the hay fever attacks, as evidenced by the findings that oxatomide patients had fewer complaint-days, and that more of these patients were rated by the investigators to have excellent or good results. Apart from daytime fatigue, transient in several patients, no oxatomide-induced side-effects were found.


Subject(s)
Diphenhydramine/therapeutic use , Piperazines/therapeutic use , Rhinitis, Allergic, Seasonal/drug therapy , Adolescent , Adult , Child , Clinical Trials as Topic , Diphenhydramine/adverse effects , Double-Blind Method , Fatigue/chemically induced , Female , Humans , Male , Piperazines/adverse effects
10.
Hum Genet ; 33(2): 189-92, 1976 Jul 27.
Article in English | MEDLINE | ID: mdl-939572

ABSTRACT

Association, in one patient, of the following malformations: brachydactylia of all segments but terminal phalanges; proximal symphalangism of many fingers and toes; abnormalities of carpal and tarsal bones; partial duplication of both big toes; mild hypertelorism. Genetic transmission seems to be recessive autosomal.


Subject(s)
Fingers/abnormalities , Toes/abnormalities , Abnormalities, Multiple/genetics , Aged , Female , Genes, Recessive , Humans
SELECTION OF CITATIONS
SEARCH DETAIL
...